Hanall Biopharma Co., Ltd. 009420
KRX · South Korea · Health Technology
KRW 48,500.00+4,400.00 (+9.98%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.
As global markets navigate a period of cautious investor sentiment and mixed economic signals, Asian stock markets have shown resilience, with some indices recording gains despite broader uncertainties. In this environment, identifying stocks that may be undervalued relative to their intrinsic value can offer intriguing opportunities for investors seeking to capitalize on potential market inefficiencies.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.